Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

T-lymphocytes have the potential to recognize cancer antigens as foreign and therefore eliminate them. However, immune checkpoints such as cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and programmed cell death (PD)-1 receptor and its ligands (PD-L1, PD-L2) suppress the activity of T-lymphocyte...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Pharmacogenomics and personalized medicine Ročník 7; číslo default; s. 357 - 365
Hlavní autoři:	Postow, Michael, Momtaz, Parisa
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	New Zealand Dove Medical Press Limited 01.01.2014 Taylor & Francis Ltd Dove Medical Press
Témata:	Antigens Apoptosis Biomarkers Cancer Cancer therapies Care and treatment Cell death Cytokines Cytotoxicity Dendritic cells FDA approval Genetic aspects Health aspects Homeostasis Immune checkpoint Immune system Immunotherapy Innovations Ligands Lymphocytes Lymphoma Melanoma Metastasis Monoclonal antibodies PD-1 protein PD-L1 protein Review Skin cancer Targeted cancer therapy Vaccines New York United States > US programmed cell death protein-1 cytotoxic T-lymphocyte antigen 4 immunotherapy immune checkpoints
ISSN:	1178-7066, 1178-7066
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!